


# 'Lnc-ing' T<sub>reg</sub> cells to the aging liver

Yonghe Ma &amp; Haiming Cao

 Check for updates

Li and colleagues address the effect of regulatory T (T<sub>reg</sub>) cells on the aging process and the role of long non-coding RNAs in T<sub>reg</sub> cell function. They show that a T<sub>reg</sub> cell-specific and age-induced long non-coding RNA, *Altre*, protects the aging liver from age-related apoptosis and metabolic abnormalities.


Aging is associated with marked changes in immunity. Age-induced decline in immune function (known as 'immunosenescence'<sup>1</sup>) has become common knowledge in the post COVID-19 era. Aging also causes chronic low-grade inflammation – often termed inflammaging<sup>2</sup> – that contributes to the development of metabolic diseases in older adults. In recent years, regulatory T (T<sub>reg</sub>) cells and long non-coding RNAs (lncRNAs) have emerged as two important regulatory elements of the immune system at cellular and molecular levels, respectively. The effect of T<sub>reg</sub> cell function on the aging process and the role of lncRNAs in T<sub>reg</sub> cells, however, are poorly understood. In this issue of *Nature Aging*, Li and colleagues<sup>3</sup> simultaneously addressed both questions by delineating an aging-induced, T<sub>reg</sub> cell-expressed lncRNA, which they name *Altre* (for 'aging liver T<sub>reg</sub>-expressed non-protein-coding RNA'). They demonstrated that *Altre* has an important role in maintaining the immune-repressive hemostasis of T<sub>reg</sub> cells in the aging liver and protects that liver from developing age-related pathologies. This work supports the vital role of liver-localized T<sub>reg</sub> cells in preventing

inflammaging and highlights the potential of T<sub>reg</sub> cell-specific lncRNAs as therapeutic targets in age-related liver disorders.

T<sub>reg</sub> cells are a unique type of T lymphocyte and function as potent regulators of immune responses by suppressing hyperstimulation or autoreactivity of the immune system<sup>4</sup>. lncRNAs are transcripts that are at least 200-nt long and have no predicted coding potential. Currently, over 60,000 lncRNAs – or three times the total number of protein-coding genes – have been identified<sup>5,6</sup>, and lncRNAs have been shown to have widespread roles in cell biology and physiology<sup>7</sup>. The authors started their work by performing a careful screen of lncRNAs that were specifically expressed in T<sub>reg</sub> cells and correlated with aging processes. It is currently unknown what fraction of the vast number of lncRNAs are functional. Furthermore, unlike protein-coding genes, the sequence–function relationship of lncRNAs is poorly understood and it is difficult to use sequence features to place lncRNAs in a biological context. Currently, one of the few proven methods to identify functional lncRNAs is to use information on how they are regulated to connect them to specific functions, but it is often necessary to overlap multiple datasets of similar regulations to identify high-confidence 'hits'<sup>8,9</sup>. That is exactly what these authors did. They overlapped three lncRNAs datasets to identify two lncRNAs that could have functional roles in T<sub>reg</sub> cells during the aging process; only one showed expression change with aging by experimental validation. The authors named this lncRNA *Altre* and demonstrated it is highly enriched in the nucleus and shows no protein-coding potential.

To study the physiological role of *Altre* in T<sub>reg</sub> cells, the authors generated two sets of *Altre*-knockout mice. They first generated mice in which *Altre* was conditionally knocked out in T cells, and found

**Fig. 1 | *Altre* maintains immune-metabolic homeostasis in the aging liver by interacting with YY1 to regulate mitochondrial-related gene expression.** Induced by aging, nucleus-localized *Altre* sequesters YY1 (a corepressor that interferes with transcription factor (TF) binding to the promoters of genes in regulating normal mitochondrial physiology (for example, *Micu2*, *Tmem160* and *Mcur1*)), thus sustaining mitochondrial integrity (left). When *Altre* is depleted, YY1 is released and binds to the promoters. As a result, the transcription of mitochondrial genes is repressed, which leads to mitochondrial reactive oxygen species (ROS) production and T<sub>reg</sub> cell apoptosis. Liver inflammation, steatosis and fibrosis subsequently occur, owing to the loss of immune-tolerance protection from T<sub>reg</sub> cells.



no significant differences in  $T_{reg}$  cell differentiation and suppressive function or in  $T_{reg}$  cell-related pathologies in young mice. To exclude the involvement of other T cells, they subsequently generated a  $T_{reg}$  cell-specific deletion of *Altre*. In this model, the percentage of  $T_{reg}$  cells in the liver was normal in young mice but was significantly decreased at 14 months of age.  $T_{reg}$  cells are generated in the thymus, secondary lymphoid organs (that is, spleen and lymph node) and a range of peripheral tissues. The authors found that the reduction of the  $T_{reg}$  cell population occurred predominantly in the liver, which thus presented them with an opportunity to study the effect of  $T_{reg}$  cells (and the underlying mechanisms) on the liver aging process.

To identify the cause of the change in the liver  $T_{reg}$  cell population after *Altre* depletion in aging mice, the authors explored the two obvious possibilities: cell proliferation or apoptosis. They quickly excluded the former; moreover, *Altre* only blocked  $T_{reg}$  cell apoptosis and did not affect their suppressive functions in the microenvironment of the aged liver, which indicates that the ‘quantity’ – but not the ‘quality’ – of liver  $T_{reg}$  cells is changed in aged *Altre*-knockout mice.

Aging induces or potentiates an array of pathological conditions in the liver. Having found a reduced  $T_{reg}$  cell population in the aging livers of mice with  $T_{reg}$  cell-specific knockout of *Altre*, the authors further examined whether *Altre* affected liver pathogenesis during aging. They found more-severe hepatic damage and fibrosis in aged, but not in young, *Altre*-knockout mice. Moreover, the prolonged aging process (>18 months old) caused a higher prevalence of liver cancer and a lower survival rate in the knockout group compared with wild-type littermates. This coincided with significantly increased pro-inflammation cell subsets in aging knockout mice. The observed phenotypes are typical manifestation of inflammaging, which suggests that proper  $T_{reg}$  cell function in the aging liver is an important safeguarding mechanism against excessive activation of the immune system.

The authors also asked what mechanism is behind the  $T_{reg}$  cell apoptosis induced by *Altre* deletion in aged mice. By analyzing differentially expressed genes in aged groups between *Altre*-knockout and wild-type mice, the authors discovered substantial changes in pathways related to cellular metabolic process, T cell function and cellular response to oxidative stress. Consistent with the changes in gene expression, mitochondrial-mediated metabolic assays showed that *Altre* deletion in aged  $T_{reg}$  cells led to impaired mitochondrial function and metabolic perturbations and, subsequently, apoptosis. Furthermore, *Altre* was shown to bind to *ying yang 1* (*YY1*), a dual-function transcriptional factor that can serve as a transcriptional activator or repressor<sup>10</sup>. By performing chromatin immunoprecipitation, the authors validated that *Altre* attenuated the binding between *YY1* and the promoters of its regulated genes, particularly those involved in mitochondrial function (such as *Micu2*, *Tmem160* and *Mcur1*). This body of evidence thus supports that *Altre* interacts with *YY1* to prevent its chromatin binding, relieving its suppression on a group of mitochondrial gene expressions. On the contrary, deletion of *Altre* led to enhanced *YY1* binding to the promoters and reduced levels of these mitochondrial genes in aged  $T_{reg}$  cells, and, eventually, to apoptosis (Fig. 1).

There are two remaining questions that arose from this study and merit further investigation. First, the relevance of *Altre* to human aging needs to be explored. It is known that lncRNAs are much less conserved than protein-coding genes, at least based on their primary sequence<sup>11</sup>. But lncRNAs might conserve their function across species independently of their sequence. For example, a pair of positionally conserved lncRNAs, which are localized in the syntenic regions of human and mouse genomes, have recently been shown to modulate immune response in both humans and mice<sup>12</sup>. Thus, if a homolog of *Altre* in humans exists then how it functions needs to be carefully studied. In addition, the authors imply that *Altre* could be a therapeutic target for age-related pathologies based on the protective role of *Altre*, but the potential risk of enhancing *Altre* function needs to be first excluded. Based on the study, it is anticipated that further activating *Altre* would increase the  $T_{reg}$  cell population in the liver of aging mice. As the immunity of the liver is an important part of the entire defense system against pathogens, the downsides of an increased  $T_{reg}$  cell population and reduced immunity in the liver – however slight they might be – need to be examined. More specifically, it needs to be ascertained whether, under conditions in which the immune system is challenged, activation of *Altre* causes oversuppression of the immune response and thus immunodeficiency. It is comforting that the authors have shown that *Altre*-knockout mice show no negative effect on immune function, but the effect of increased *Altre* expression or function in young and aging mice also needs to be investigated.

The role of lncRNAs in  $T_{reg}$  cells and the influence of  $T_{reg}$  cells on the aging process are both important questions. This study provides an intriguing proof-of-concept example that a  $T_{reg}$  cell-specific lncRNA can serve as a safeguarding mechanism against inflammaging and age-related metabolic abnormalities, which could open up avenues to understand and remedy aging-induced pathologies.

**Yonghe Ma & Haiming Cao**  

Cardiovascular Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

 e-mail: [haiming.cao@nih.gov](mailto:haiming.cao@nih.gov)

Published online: 8 June 2023

## References

1. Nikolich-Zugich, J. *Nat. Immunol.* **19**, 10–19 (2018).
2. Franceschi, C. et al. *Ann. NY Acad. Sci.* **908**, 244–254 (2000).
3. Ding, C. et al. *Nat. Aging* <https://doi.org/10.1038/s43587-023-00428-8> (2023).
4. Sakaguchi, S. *Annu. Rev. Immunol.* **22**, 531–562 (2004).
5. Seifuddin, F. et al. *Sci. Data* **7**, 326 (2020).
6. Iyer, M. K. et al. *Nat. Genet.* **47**, 199–208 (2015).
7. Statello, L., Guo, C. J., Chen, L. L. & Huarte, M. *Nat. Rev. Mol. Cell Biol.* **22**, 96–118 (2021).
8. Ruan, X. et al. *Nat. Commun.* **11**, 45 (2020).
9. Ruan, X. et al. *J. Clin. Invest.* **131**, e136336 (2021).
10. Shi, Y., Lee, J. S. & Galvin, K. M. *Biochim. Biophys. Acta* **1332**, F49–F66 (1997).
11. Necsulca, A. et al. *Nature* **505**, 635–640 (2014).
12. Vollmers, A. C. et al. *Proc. Natl Acad. Sci. USA* **118**, e2016648118 (2021).

## Competing interests

The authors declare no competing interests.